Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Neurology

Does Wilson Disease Treatment Make Symptoms Worse at First?

At a Glance

Yes, Wilson disease medications can sometimes make neurological symptoms worse at first. This happens when treatments pull copper from the liver into the blood too quickly, allowing it to temporarily reach the brain. Contact your doctor immediately if your symptoms worsen.

Yes, it is possible for neurological symptoms like tremors to get worse when you first start taking medication for Wilson disease. This is a recognized medical phenomenon known as paradoxical neurological worsening [1][2]. It can be a frightening experience, but understanding why it happens and how doctors manage it can help you navigate this phase of treatment safely.

What is Paradoxical Neurological Worsening?

When you are diagnosed with Wilson disease, your body has accumulated dangerously high levels of copper, primarily in your liver and brain [3][4]. The most common first-line treatments are chelator medications, such as D-penicillamine or trientine. A chelator’s job is to bind to excess copper and pull it out of your tissues so your body can excrete it in your urine.

While the exact biological mechanism is not definitively proven, the leading medical explanation for this worsening involves how quickly these medications work [5][6]. When a chelator suddenly pulls a large amount of copper out of the liver, that copper enters the bloodstream [5][6]. Before the kidneys can filter all of this newly freed copper into the urine, there is a temporary surge of “free copper” circulating in the blood [6][7]. This free copper can cross the blood-brain barrier and deposit in the brain’s neurological centers, temporarily aggravating symptoms like tremors, muscle stiffness, or difficulty speaking [7][6].

When Does It Happen, and How Common Is It?

The “danger window” for this complication is early in treatment. Research shows that if neurological worsening is going to happen, it typically occurs within the first few months of starting therapy (averaging around 2 to 3 months) [8]. Because of this, your doctor will closely monitor you during your first six months of treatment.

Recent studies estimate that this early worsening occurs in about 11% to 22% of patients starting anti-copper therapy, though older historical estimates placed the risk between 10% and 50% depending on the specific drug and severity of the disease [8][9][10]. Some studies suggest it happens more frequently with D-penicillamine than with zinc salts, though D-penicillamine is still widely used because it is a highly powerful and effective drug for rapidly clearing copper [5][1].

It is important to note that if you were diagnosed with primarily liver (hepatic) symptoms and no neurological issues, your risk of experiencing this complication is significantly lower [5]. However, if you already have neurological symptoms, certain factors may put you at a higher risk for initial worsening, including [10][8]:

  • Having severe neurological symptoms or specific brain lesions on an MRI at the time of diagnosis
  • Having a younger age of onset for the disease
  • Experiencing dystonia (involuntary muscle contractions that cause repetitive or twisting movements) at diagnosis
  • Taking certain medications for nausea or psychiatric conditions (dopamine receptor antagonists)

Why Doctors Start Medications Slowly

Because paradoxical neurological worsening is a known risk, specialists deliberately use a “start low and go slow” approach when prescribing chelating therapies [5]. By introducing the medication at a very low dose and gradually increasing it over time, doctors aim to prevent a massive, sudden release of copper from the liver into the bloodstream [5]. This controlled pace gives the kidneys enough time to safely filter and excrete the mobilized copper without overwhelming the brain.

What to Do If Your Symptoms Worsen

If you have just started medication and notice that your tremors are getting worse, or if you develop new symptoms such as increased rigidity, difficulty walking, speech issues, or trouble swallowing, you must contact your neurologist or hepatologist immediately [10].

Do not wait to see if the symptoms improve on their own, and never stop taking your medication without your doctor’s guidance. While neurological worsening can sometimes be difficult to reverse if left unaddressed, the deliberate “start low and go slow” protocol combined with reporting symptoms early is exactly how doctors prevent permanent damage [5][8]. When caught and managed early, deterioration is completely reversible in over half of patients, though recovery can take several months [8].

Your medical team may choose to adjust your current dosage to slow down the copper mobilization. Alternatively, they may switch you to a different treatment, such as trientine (another chelator) or zinc therapy, which may alter the rate of copper mobilization and help stabilize your symptoms [11][12].

Common questions in this guide

Why do my tremors get worse after starting Wilson disease medication?
Chelator medications pull excess copper from your liver into your bloodstream so your body can remove it. Sometimes, this causes a temporary surge of free copper that reaches the brain, which can aggravate symptoms like tremors or muscle stiffness.
How common is paradoxical neurological worsening in Wilson disease?
Recent studies estimate that this early worsening occurs in about 11 to 22 percent of patients starting anti-copper therapy. It is much less common if you were diagnosed with only liver symptoms and no neurological issues.
When does neurological worsening usually happen after starting treatment?
If paradoxical neurological worsening is going to happen, it typically occurs within the first few months of starting therapy. The average time it begins is around two to three months into treatment.
Why is my doctor starting my medication at such a low dose?
Because of the risk of neurological worsening, doctors use a start low and go slow approach. By introducing the medication at a low dose and gradually increasing it, they give your kidneys time to safely filter the mobilized copper without overwhelming your brain.
What should I do if my Wilson disease symptoms get worse on medication?
You must contact your neurologist or hepatologist immediately. Do not stop taking your medication without your doctor's guidance, as they can safely adjust your dosage or switch your treatment to help stabilize your symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific risk of experiencing paradoxical neurological worsening based on my current symptoms and brain MRI?
  2. 2.Why did you choose this specific medication (e.g., D-penicillamine vs. trientine or zinc) for my initial treatment?
  3. 3.How slowly will we be increasing my medication dose to minimize the risk of a sudden copper surge?
  4. 4.During these first few months, at what point should I call the clinic if I notice my tremors getting worse?
  5. 5.How frequently will you monitor my blood and urine copper levels during the first six months of therapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Comparison of the Effectiveness and Safety of d-Penicillamine and Zinc Salt Treatment for Symptomatic Wilson Disease: A Systematic Review and Meta-Analysis.

    Tang S, Bai L, Hou W, et al.

    Frontiers in pharmacology 2022; (13()):847436 doi:10.3389/fphar.2022.847436.

    PMID: 35370752
  2. 2

    Wilson disease-treatment perspectives.

    Litwin T, Dzieżyc K, Członkowska A

    Annals of translational medicine 2019; (7(Suppl 2)):S68 doi:10.21037/atm.2018.12.09.

    PMID: 31179305
  3. 3

    Copper deposition in oligodendroglial cells in an autopsied case of hepatolenticular degeneration.

    Nishimuta M, Masui K, Yamamoto T, et al.

    Neuropathology : official journal of the Japanese Society of Neuropathology 2018; (38(3)):321-328 doi:10.1111/neup.12456.

    PMID: 29468756
  4. 4

    Wilson disease.

    Członkowska A, Litwin T, Dusek P, et al.

    Nature reviews. Disease primers 2018; (4(1)):21 doi:10.1038/s41572-018-0018-3.

    PMID: 30190489
  5. 5

    Difficulties in diagnosis and treatment of Wilson disease-a case series of five patients.

    Członkowska A, Dzieżyc-Jaworska K, Kłysz B, et al.

    Annals of translational medicine 2019; (7(Suppl 2)):S73 doi:10.21037/atm.2019.02.37.

    PMID: 31179310
  6. 6

    Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update.

    Teschke R, Eickhoff A

    International journal of molecular sciences 2024; (25(9)) doi:10.3390/ijms25094753.

    PMID: 38731973
  7. 7

    Therapeutic strategies in Wilson disease: pathophysiology and mode of action.

    Stremmel W, Weiskirchen R

    Annals of translational medicine 2021; (9(8)):732 doi:10.21037/atm-20-3090.

    PMID: 33987430
  8. 8

    Early neurological worsening in patients with Wilson's disease.

    Litwin T, Dzieżyc K, Karliński M, et al.

    Journal of the neurological sciences 2015; (355(1-2)):162-7.

    PMID: 26071888
  9. 9

    Early neurological deterioration in Wilson's disease: a systematic literature review and meta-analysis.

    Antos A, Członkowska A, Smolinski L, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(10)):3443-3455 doi:10.1007/s10072-023-06895-6.

    PMID: 37311952
  10. 10

    Clinical and Genetic Analysis in Neurological Wilson's Disease Patients With Neurological Worsening Following Chelator Therapy.

    Hou H, Chen D, Liu J, et al.

    Frontiers in genetics 2022; (13()):875694 doi:10.3389/fgene.2022.875694.

    PMID: 35444691
  11. 11

    Management of Children and Adolescents with Wilson Disease and Neurological Worsening Following D-Penicillamine Therapy: A Single Centre Experience.

    Kumar M, Murugan TP, Lionel AP, et al.

    Annals of Indian Academy of Neurology 2022; (25(4)):698-702 doi:10.4103/aian.aian_519_21.

    PMID: 36211139
  12. 12

    A study of susceptibility-weighted imaging in patients with Wilson disease during the treatment of metal chelator.

    Zhou X, Xiao X, Li XH, et al.

    Journal of neurology 2020; (267(6)):1643-1650 doi:10.1007/s00415-020-09746-y.

    PMID: 32060651

This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist or hepatologist immediately if you experience worsening symptoms after starting treatment.

Get notified when new evidence is published on Wilson disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.